On this page Agenda Applications for consideration at this meeting 1485 Sentinel Lymph Node Biopsy for intermediate thickness melanoma 1486 Programmed cell death ligand 1 (PD-L1) testing to determine PBS access to durvalumab or durvalumab/tremelimumab as 1st line therapy for patients with advanced or metastatic non-small-cell lung cancer (NSCLC) 1490 Breast Magnetic Resonance Imaging for Breast Implant Associated Anaplastic Large Cell Lymphoma 1493 Transarterial radioembolisation with yttrium-90 (TARE-Y) for the treatment of unresectable hepatocellular carcinoma Related information Committee: PICO Advisory Subcommittee (PASC)